Shanghai Bio-heart Biological Technology Co Ltd (02185.HK)

Shanghai Bio-Heart Biological Technology Co., Ltd. engages in the research and development of interventional cardiovascular device therapies. The company is headquartered in Shanghai, Shanghai and currently employs 65 full-time employees. The company went IPO on 2021-12-23. The Company’s products primarily include the Bioheart bioresorbable scaffold (BRS) system for percutaneous coronary intervention procedures, Iberis second-generation renal denervation (RDN) system for the treatment of hypertension, and drug coated balloon (DCB) for the treatment of in-stent restenosis. The firm primarily operates its business in the domestic market.